Stay updated on Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe completed phase 3 KEYNOTE-006 study record is displayed, with details on pembrolizumab and ipilimumab treatment arms, participant criteria, measured outcomes, and related publications.SummaryDifference51%

- Check16 days agoChange DetectedThe site revision label changed from v3.7.2 to v3.8.0, while the page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check23 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The requested study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check30 days agoChange DetectedThe footer revision number changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1; the 403 error page otherwise remains the same.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now shows a 403 Forbidden error with the site chrome (header/footer), replacing the previously visible study details and related content with an access-denied screen.SummaryDifference18%

Stay in the know with updates to Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Ipilimumab in Melanoma Clinical Trial page.